Navigation Links
FDA Clears Caspofungin (Cancidas(R)) Susceptibility Testing for TREK Sensititre(R) YeastOne(R) in Vitro Diagnostics (IVD) Product Line
Date:7/7/2009

CLEVELAND, July 7 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has received clearance from the U.S. Food and Drug Administration (FDA) to include caspofungin in its line of YeastOne susceptibility products. TREK will make the drug available on custom YeastOne formats, allowing clinicians to create the plate that best meets their requirements. The custom format complements TREK's standard IVD-cleared YeastOne product (Part No. YO-2V), which contains the four most widely-prescribed antifungals: itraconazole, fluconazole, 5 flucytosine and voriconazole.

Physicians typically prescribe intravenous caspofungin therapy when other treatment regimes are not well tolerated or have failed. The first in a new class of enzyme-inhibiting antifungal agents, caspofungin, is FDA-cleared for treatment of candidiasis in adults and pediatric patients. Candidiasis is a fungal infection that can be life-threatening if it becomes systemic.

"This is the second FDA clearance we have received this year for our YeastOne product line," said President of Magellan's diagnostics business, James Whelan. "Last month, we announced the addition of voriconazole to our standard YeastOne IVD plate. Our goal with IVD susceptibility products is to increase reportable compounds and treatment options for clinicians. Customers need plates that allow them to report timely results using a fully reimbursable format. We are committed to taking our products through the FDA clearance process where feasible and appropriate. Because pharmaceutical companies use our Sensititre susceptibility system during drug development, we often get early access to the latest therapeutics and are able to provide clinicians with the widest possible drug choices. A wide array of cost-effective plate formats that deliver timely and reliable results not only supports pharmacy cost-control efforts - it improves patient care."

About the Sensititre YeastOne Product Line

TREK offers a wide range of FDA cleared and research-use-only (RUO) YeastOne dried microbroth dilution plates with a variety of drug options. The products provide physicians and researchers with fast, cost-effective, and reliable results. Plates feature standard 24-hour incubation, easy-to-read colorimetric endpoints, and on-scale QC ranges, making antifungal susceptibility testing a viable in-house procedure for virtually any size laboratory.

  • YeastOne for IVD -- The YeastOne product line received its first FDA clearance in 2001 and has been widely recognized for accuracy. TREK's standard IVD YeastOne plate (Part No. YO-2V) is the only IVD-labeled susceptibility product that is FDA-cleared for testing Candida species isolates against four commonly prescribed FDA-cleared antifungal agents: voriconazole, fluconazole, 5-flucytosine and itraconazole.

  • YeastOne for RUO -- TREK's standard RUO YeastOne plate (Part No. YO-9*) includes nine antimicrobics: anidulafungin, amphotericin B, caspofungin, fluconazole, 5 flucytosine, itraconazole, micafungin, posaconazole and voriconazole.

*For research use only. Not for use in diagnostic procedures.

  • Custom YeastOne plates -- Labs can customize plates by selecting from nine antifungal agents, including five cleared antifungal compounds, and specifying format and drug concentrations to create the best plate for their particular needs. Small minimum order quantities allow for better cost and inventory control. To learn more about custom plates, call customer service toll-free at 800 871-8909. Outside the US and Canada, dial +44 (0) 1342-318777 or e-mail: mmansfield@trekds.co.uk

About TREK Diagnostic Systems (www.trekds.com)

A Magellan Biosciences diagnostics business, TREK is a global manufacturer and distributor of automated systems and consumable products for microbiology-based diagnostic testing designed to improve patient outcomes. Signature product lines include VersaTREK(R), Sensititre(R), Vizion(R), alamarBlue(R), para-JEM(R), YeastOne(R), onSite(R) and TREK Lab Services. TREK is committed to delivering the highest quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide.

Cancidas is a registered trademark of Merck & Co., Inc.


'/>"/>
SOURCE TREK Diagnostic Systems
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Federal Trade Commission Clears Kyphons Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
3. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
4. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
5. New filter clears up fiber optic communications
6. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
7. Device That Clears Debris From Artery Aids Blood Flow in PCI
8. FDA Clears First Medical Product Made From Yulex(R) Natural Rubber
9. FDA Clears New Applicators for Endometrial Cancer Treatment With Xofts Axxent(R) Electronic Brachytherapy System
10. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
11. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis Foundation, the ... and advocacy. Founded in 2010 in memory of a single-parent mom and kindergarten ... become the most-consulted source for patient-focused information on C. diff infections in the ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 A new ... Analysis and Industry Forecast, 2014-2022 ," the global market was valued at $6,769 ... a CAGR of 9.6% from 2016 to 2022. ... Allied ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:4/19/2017)... Va. and WESTMINSTER, Colo. ... Finance LLC ("Oxford"), an industry-leading specialty finance firm ... healthcare services companies, today announced the closing of ... Cerapedics Inc. ("Cerapedics") a privately-held orthobiologics company engaged ... substitute products for the treatment of orthopedic injuries. ...
(Date:4/19/2017)...   Thermo Fisher Scientific Inc . today ... SEpsis (MOSES) Study have been published in the ... Medicine . Researchers from the study, titled "Serial ... From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study," ... assay to assess risk for 28 day all-cause ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):